Contemporary management of diffuse large B-cell lymphoma in Japan

被引:0
作者
Miura, Katsuhiro [1 ,2 ]
Takahashi, Hiromichi [1 ]
Nishimaki-Watanabe, Haruna [3 ]
Hamada, Takashi [1 ]
Uchiike, Akihiro [2 ,4 ]
Tsutsumi, Daisuke [2 ,4 ]
Ohtake, Shimon [1 ]
Iizuka, Kazuhide [1 ,5 ]
Koike, Takashi [1 ]
Kurihara, Kazuya [1 ]
Endo, Toshihide [1 ]
Hayama, Tatsuya [2 ,4 ]
Nakagawa, Masaru [6 ]
Iriyama, Noriyoshi [1 ,7 ]
Hatta, Yoshihiro [1 ,8 ]
Nakamura, Hideki [1 ]
机构
[1] Nihon Univ, Dept Hematol & Rheumatol, Sch Med, 30-1 Oyaguchikamicho, Tokyo, Tokyo 1738610, Japan
[2] Nihon Univ, Tumor Ctr, Itabashi Hosp, Tokyo, Japan
[3] Nihon Univ, Dept Pathol & Microbiol, Div Oncol Pathol, Sch Med, Tokyo, Japan
[4] Nihon Univ, Dept Pharm, Itabashi Hosp, Tokyo, Japan
[5] Nihon Univ, Dept Pathol & Microbiol, Div Lab Med, Sch Med, Tokyo, Japan
[6] Kasukabe Med Ctr, Dept Hematol, Kasukabe city, Japan
[7] NHO Saitama Hosp, Dept Hematol & Rheumatol, Wako, Japan
[8] Akiru Municipal Med Ctr, Dept Hematol, Deputy Chief Med Clin, Akiruno City, Japan
关键词
Cost-effectiveness; geriatric assessment; diffuse large B-cell lymphoma; healthcare insurance system; Japan; RELATIVE DOSE INTENSITY; OF-ORIGIN SUBTYPES; THP-COP THERAPY; ELDERLY-PATIENTS; SINGLE-ARM; ATTENUATED IMMUNOCHEMOTHERAPY; OLDER PATIENTS; ADVANCED-STAGE; OPEN-LABEL; PHASE-II;
D O I
10.1080/14737140.2025.2490283
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionDespite the heterogeneity of diffuse large B-cell lymphoma (DLBCL), treatment approaches are remarkably well-standardized. However, its management differs according to socio-economic and medical environments.Areas coveredThis review analyzed the latest trends in DLBCL diagnosis and treatment in Japan, where the national universal healthcare insurance covers the cost of novel modalities, such as polatuzumab vedotin, chimeric antigen receptor T cells (CAR-T), or bispecific antibodies (BsAb). Given the particularly high incidence, we spotlighted DLBCL in older adults. CD5-positive (CD5+) DLBCL and intravascular large B-cell lymphoma (IVLBCL) were also discussed based on the leading trials conducted in Japan.Expert opinionThe accurate pathologic diagnosis of DLBCL made by experts or via consultation networks is essential, and an emerging genomic assay will contribute to future precision approaches. Although polatuzumab vedotin is frequently used in the first-line treatment of patients with advanced disease, its application should be carefully analyzed. As the number of older patients increases, the importance of pre-treatment geriatric assessment becomes apparent. CD5+ DLBCL and IVLBCL adopt distinct strategies with high-dose methotrexate, but their benefits warrant further evaluation. CAR-T and BsAb are increasingly used to treat patients with relapsed and refractory diseases. A cost-effective evaluation of these novel approaches is required.
引用
收藏
页码:551 / 559
页数:9
相关论文
共 87 条
[1]   The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms [J].
Alaggio, Rita ;
Amador, Catalina ;
Anagnostopoulos, Ioannis ;
Attygalle, Ayoma D. ;
Araujo, Iguaracyra Barreto de Oliveira ;
Berti, Emilio ;
Bhagat, Govind ;
Borges, Anita Maria ;
Boyer, Daniel ;
Calaminici, Mariarita ;
Chadburn, Amy ;
Chan, John K. C. ;
Cheuk, Wah ;
Chng, Wee-Joo ;
Choi, John K. ;
Chuang, Shih-Sung ;
Coupland, Sarah E. ;
Czader, Magdalena ;
Dave, Sandeep S. ;
de Jong, Daphne ;
Du, Ming-Qing ;
Elenitoba-Johnson, Kojo S. ;
Ferry, Judith ;
Geyer, Julia ;
Gratzinger, Dita ;
Guitart, Joan ;
Gujral, Sumeet ;
Harris, Marian ;
Harrison, Christine J. ;
Hartmann, Sylvia ;
Hochhaus, Andreas ;
Jansen, Patty M. ;
Karube, Kennosuke ;
Kempf, Werner ;
Khoury, Joseph ;
Kimura, Hiroshi ;
Klapper, Wolfram ;
Kovach, Alexandra E. ;
Kumar, Shaji ;
Lazar, Alexander J. ;
Lazzi, Stefano ;
Leoncini, Lorenzo ;
Leung, Nelson ;
Leventaki, Vasiliki ;
Li, Xiao-Qiu ;
Lim, Megan S. ;
Liu, Wei-Ping ;
Louissaint, Abner, Jr. ;
Marcogliese, Andrea ;
Medeiros, L. Jeffrey .
LEUKEMIA, 2022, 36 (07) :1720-1748
[2]   Use of random skin biopsy for diagnosis of intravascular large B-Cell lymphoma [J].
Asada, Noboru ;
Odawara, Jun ;
Kimura, Shun-Ichi ;
Aoki, Takatoshi ;
Yamakura, Masayuki ;
Takeuchi, Masami ;
Seki, Reiko ;
Tanaka, Atsushi ;
Matsue, Kosei .
MAYO CLINIC PROCEEDINGS, 2007, 82 (12) :1525-1527
[3]   The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee [J].
Campo, Elias ;
Jaffe, Elaine S. ;
Cook, James R. ;
Quintanilla-Martinez, Leticia ;
Swerdlow, Steven H. ;
Anderson, Kenneth C. ;
Brousset, Pierre ;
Cerroni, Lorenzo ;
de Leval, Laurence ;
Dirnhofer, Stefan ;
Dogan, Ahmet ;
Feldman, Andrew L. ;
Fend, Falko ;
Friedberg, Jonathan W. ;
Gaulard, Philippe ;
Ghia, Paolo ;
Horwitz, Steven M. ;
King, Rebecca L. ;
Salles, Gilles ;
San-Miguel, Jesus ;
Seymour, John F. ;
Treon, Steven P. ;
Vose, Julie M. ;
Zucca, Emanuele ;
Advani, Ranjana ;
Ansell, Stephen ;
Au, Wing-Yan ;
Barrionuevo, Carlos ;
Bergsagel, Leif ;
Chan, Wing C. ;
Cohen, Jeffrey I. ;
d'Amore, Francesco ;
Davies, Andrew ;
Falini, Brunangelo ;
Ghobrial, Irene M. ;
Goodlad, John R. ;
Gribben, John G. ;
Hsi, Eric D. ;
Kahl, Brad S. ;
Kim, Won-Seog ;
Kumar, Shaji ;
LaCasce, Ann S. ;
Laurent, Camille ;
Lenz, Georg ;
Leonard, John P. ;
Link, Michael P. ;
Lopez-Guillermo, Armando ;
Mateos, Maria Victoria ;
Macintyre, Elizabeth ;
Melnick, Ari M. .
BLOOD, 2022, 140 (11) :1229-1253
[4]   Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma [J].
Carson, Kenneth R. ;
Riedell, Peter ;
Lynch, Ryan ;
Nabhan, Chadi ;
Wildes, Tanya M. ;
Liu, Weijian ;
Gantia, Arun ;
Roop, Ryan ;
Sanfilippo, Kristen M. ;
O'Brian, Katiuscia ;
Liu, Jingxia ;
Bartlett, Nancy L. ;
Cashen, Amanda ;
Wagner-Johnston, Nina ;
Fehniger, Todd A. ;
Colditz, Graham A. .
JOURNAL OF GERIATRIC ONCOLOGY, 2015, 6 (03) :211-218
[5]   Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [J].
Chapuy, Bjoern ;
Stewart, Chip ;
Dunford, Andrew J. ;
Kim, Jaegil ;
Kamburov, Atanas ;
Redd, Robert A. ;
Lawrence, Mike S. ;
Roemer, Margaretha G. M. ;
Li, Amy J. ;
Ziepert, Marita ;
Staiger, Annette M. ;
Wala, Jeremiah A. ;
Ducar, Matthew D. ;
Leshchiner, Ignaty ;
Rheinbay, Ester ;
Taylor-Weiner, Amaro ;
Coughlin, Caroline A. ;
Hess, Julian M. ;
Pedamallu, Chandra S. ;
Livitz, Dimitri ;
Rosebrock, Daniel ;
Rosenberg, Mara ;
Tracy, Adam A. ;
Horn, Heike ;
van Hummelen, Paul ;
Feldman, Andrew L. ;
Link, Brian K. ;
Novak, Anne J. ;
Cerhan, James R. ;
Habermann, Thomas M. ;
Siebert, Reiner ;
Rosenwald, Andreas ;
Thorner, Aaron R. ;
Meyerson, Matthew L. ;
Golub, Todd R. ;
Beroukhim, Rameen ;
Wulf, Gerald G. ;
Ott, German ;
Rodig, Scott J. ;
Monti, Stefano ;
Neuberg, Donna S. ;
Loeffler, Markus ;
Pfreundschuh, Michael ;
Truemper, Lorenz ;
Getz, Gad ;
Shipp, Margaret A. .
NATURE MEDICINE, 2018, 24 (05) :679-+
[6]   State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma [J].
Chiappella, Annalisa ;
Castellino, Alessia ;
Vitolo, Umberto .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (06) :1147-+
[7]   High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide Retrospective Study [J].
Chihara, Dai ;
Izutsu, Koji ;
Kondo, Eisei ;
Sakai, Rika ;
Mizuta, Shuichi ;
Yokoyama, Kenji ;
Kaneko, Hiroto ;
Kato, Koji ;
Hasegawa, Yuichi ;
Choul, Takaaki ;
Sugaharall, Hiroyuki ;
Henzan, Hideho ;
Sakamaki, Hisashi ;
Suzuki, Ritsuro ;
Suzumiya, Junji .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (05) :684-689
[8]   CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition [J].
Cooper, Alan ;
Tumuluru, Sravya ;
Kissick, Kyle ;
Venkataraman, Girish ;
Song, Joo Y. ;
Lytle, Andrew ;
Duns, Gerben ;
Yu, Jovian ;
Kotlov, Nikita ;
Bagaev, Aleksander ;
Hodkinson, Brendan ;
Srinivasan, Srimathi ;
Smith, Sonali M. ;
Scott, David W. ;
Steidl, Christian ;
Godfrey, James K. ;
Kline, Justin .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (04) :467-480
[9]   CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy [J].
Ennishi, D. ;
Takeuchi, K. ;
Yokoyama, M. ;
Asai, H. ;
Mishima, Y. ;
Terui, Y. ;
Takahashi, S. ;
Komatsu, H. ;
Ikeda, K. ;
Yamaguchi, M. ;
Suzuki, R. ;
Tanimoto, M. ;
Hatake, K. .
ANNALS OF ONCOLOGY, 2008, 19 (11) :1921-1926
[10]   Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma [J].
Ennishi, Daisuke ;
Hsi, Eric D. ;
Steidl, Christian ;
Scott, David W. .
CANCER DISCOVERY, 2020, 10 (09) :1267-1281